The Department of Health and Human Services announced on June 30 that it will terminate emergency-use authorization declarations for certain COVID-19 drugs and medical devices, marking a formal end to expedited pandemic-era regulatory pathways first opened in 2020.
Under the announced timeline, emergency-use authorizations for COVID-19 drugs and biological products will expire June 29, 2027, while those for medical devices will end December 26, 2026. HHS stated that the circumstances that justified the accelerated authorizations no longer exist.
Context and Background
Emergency-use authorization represents a regulatory mechanism that permits the FDA to make unapproved medical products available during public-health emergencies when no adequate alternatives exist. When the COVID-19 pandemic began in 2020, HHS issued broad EUA declarations to speed the availability of diagnostic tests, vaccines, therapeutics, and medical equipment to hospitals and the public.
The staggered end dates reflect different product categories: drugs and vaccines will retain authorization for another year, while devices such as ventilators and diagnostic equipment will lose their emergency status by year’s end. Once the authorizations expire, manufacturers of these products will need to pursue standard FDA approval pathways or discontinue distribution.
Implications for Manufacturers and Supply
The timeline gives pharmaceutical and device makers roughly six months to eighteen months to secure traditional FDA approval or exit the market. Products currently relying on emergency authorization—including some monoclonal antibody treatments and rapid diagnostic tests—will need to demonstrate safety and efficacy through conventional review processes to remain available.
The announcement aligns with the Trump administration’s broader agenda of streamlining federal health agencies and reducing what it characterizes as emergency-driven regulatory overreach. Earlier executive orders have directed HHS to review agency operations and reduce what administration officials describe as unnecessary bureaucratic barriers.
What Comes Next
Manufacturers have until the respective deadlines to submit applications for standard FDA approval or prepare for market withdrawal. The FDA will continue to review pending applications for COVID-19 products under conventional timelines. Any product that fails to secure approval before its EUA expires will no longer be legally available for distribution in the United States.
The move represents a formal acknowledgment that acute pandemic conditions no longer justify emergency regulatory pathways. As COVID-19 transitions from a declared emergency to an endemic disease, the federal government is returning COVID-related medical products to standard regulatory review.